Haemophilus influenzae type b is the commonest cause of bacterial meningitis for individuals less than 5 years old and is also an important etiological agent of penumonia, otitis media, and septic arthritis in this age group (23) . Human immunity to H. influenzae b was first elucidated by Fothergill and Wright (7) , who showed that bactericidal (BA) antibody was present at birth (via transplacental passage from the mother), declined to undetectable levels by age 6 months, reappeared by age 3 years in almost all children, and was sustained throughout adult life. The lack of BA antibodies was associated with a higher incidence ofH. influenzae b disease, and their presence implied protection from disease. More recent investigations (1, 2, 15, 24) Several questions about immunity to H. influenzae b remain to be investigated. Since childhood infection with this organism is uncommon, the almost universal age-related acquisition of protective antibodies has been termed "natural" immunity. It has been suggested that the antigenic source for these antibodies may be enteric cross-reacting bacteria which colonize the gastrointestinal tract (4).
Children surviving H. influenzae b meningitis prior to age 2 years make little or no anticapsular (AC) antibodies despite systemic infection, whereas survivors of meningitis after age 2 respond briskly (17) . Furthermore, the subsequent response to immunization with polysaccharide vaccine is blunted in children surviving H. influenzae b meningitis before age 2 years. "Immunological paralysis" has been suggested as the responsible mechanism for this apparent age-related specific suppression of immune responsiveness (17, 19 Bacteria. The strain of H. influenzae b ("Pekala" strain) and the techniques of storage and culture used in our laboratory have been previously described (13) . For the present experiments, the bacteria used were passaged either once or twice through 5-day-old rats before storage and use. Both strains of unencapsulated H. influenzae (F2 and F3) were isolated from children with otitis media. Killed bacteria for immunization and absorption were prepared by centrifugation of an overnight broth culture and resuspension in 2% neutral buffered formalin. After overnight incubation at room temperature, the bacteria were washed four times in 0.5 M phosphatebuffered saline (pH 7.1).
Stool and throat cultures. Throat swabs were planted on Levinthal "antiserum-agar" medium as previously described (9) , and rectal swabs were planted on Trypticase soy agar (Difco Laboratories, Detroit, Mich.) containing a similar amount of antiserum. Plates were incubated for 24 h at 37°C followed by 24 h at 4°C. Colonies surrounded by a precipitin halo were subcultured, and the presence of a cross-reacting antigen was confirmed by immunodiffusion (21) .
Immunological methods. Serum AC antibodies were measured by a radiolabeled, antigen-binding assay as previously described (18) . Results are expressed as micrograms of antibody protein per milliliter of serum. The minimum detectable concentration was 0.1 yg/ml. The presence or absence of serum BA activity was detected as previously described (17) . Because of the small sample size, end point titrations of BA activity were not carried out. Counterimmunoelectrophoresis for soluble type b polysaccharide antigen was performed as described (8) . The minimum detectable antigen was 30 ng/ml. Absorption of hyperimmune sera with either purified antigen or killed whole bacteria was carried out at 37°C for 2 h followed by 24 h at 4°C. Hyperimmune sera were raised in rabbits against two unencapsulated strains of H. influenzae using intravenous injections of a saline suspension of washed, formalinkilled bacteria (10'0/ml). The schedule in Table 1 was used.
These sera yielded a double precipitin line by counterimmunoelectrophoresis using a broth supernatant from an overnight culture of the homologous strain as antigen. Hyperimmune burro antiserum raised against the "Rab" strain of H. influenzae b was kindly supplied by J. B. Robbins (24) .
Animal inoculations. The techniques used to produce H. influenzae b bacteremia and meningitis by either the i.n. or i.p. route in 5-day-old rats were those of Moxon et al. (10) and Smith et al. (25) , respectively, as slightly modified by us (13) . Passive protection experiments were performed by an i.p. inoculation of 0.1 ml of the serum dilution to be tested into each of a group of six 4-day-old rats. The following day, the rats were inoculated i.p. with 104 live H. influenzae b, an inoculum that produced bacteremia in all control animals. Forty-eight hours after bacterial inoculation, 1-,ul samples of blood were obtained from the jugular vein by decapitation and were planted on antiserum-agar plates. Failure to recover any colonies ofH. influenzae b was considered positive for protection. Unprotected animals usually had colony counts greater than 104 colonyforming units per ml, and most were greater than 105 colony-forming units per ml. Fifty percent end point dilutions for protection against bacteremia were calculated by the method of Reed and Muench (20) . Meningitis was detected by histological examination of the brain as described (13) . Experimental design. In the first experiment, four litters (12 animals each) of newborn rats were housed in separate cages until they were 4 weeks old, at which time they were weaned and divided into cages containing four animals each from the same litter. Mothers were bled shortly after giving birth. Growing rats were weekly bled by cardiac puncture until age 5 weeks and then biweekly until age 15 weeks. All rats (mothers and pups) had throat and rectal swab cultures after each bleeding. By age 17 16, 1977 on November 2, 2017 by guest http://iai.asm.org/ Downloaded from greater than 104 colony-forming units per ml of blood. Bacteremic rats were identified and separated from nonbacteremic rats. A control group of 40 5-day-old rats from five litters were inoculated i.n. with saline. Bacteremic rats, rats inoculated with bacteria but who were nonbacteremic, and salinecontrol rats were housed in separate cages. The mortality in bacteremic rats was 50% (20/40) during the first 2 weeks after inoculation. However, during the first S weeks after inoculation, 17 (40%) of the 43 inoculated-but-nonbacteremic rats and 20 (50%) of the 40 saline-control rats also succumbed for unknown reasons. All surviving rats were bled by cardiac puncture at 5, 9, and 15 and "adult" levels were achieved when rats were between 9 and 11 weeks of age. By 17 weeks of age, the geometric mean antibody concentration (± standard deviation) for the entire group was 0.25 ± 0.04 ug/ml; BA activity was not detected at 7 weeks of age (despite detectable levels of AC antibody), but 46% of the sera from 15-week-old rats had BA activity. No H. influenzae b or cross-reacting bacteria were isolated from the throat or rectal cultures during this period, except for one rat whose rectal culture at 9 weeks of age yielded a single colony of a cross-reacting Bacillus species (12) .
Immunization of adult rats. Immunization of these rats at 17 weeks of age with either whole killed H. influenzae b (group A) or varying doses of polysaccharide vaccine (group B) failed to significantly increase the mean AC antibody concentration at 1 or 3 weeks postimmunization (Table 2 ). Since there was no difference in results for the different dosage groups of vaccine, the data were combined. However, the group immunized with killed bacteria (group A) did have a significant increase in the number of rats with detectable bactericidal activity (P < 0.01 using Fisher's exact test, Immune response of survivors of experimental infection. The age-related acquisition of AC antibodies among rats surviving an i.n.-induced bacteremia when they were 5 days old, rats who had been challenged but were nonbacteremic, and rats who were saline controls was not significantly different among the groups (Fig. 2) , nor was it significantly different from the unmanipulated group in the first experiment (Fig. 1) . Table 4 shows the AC antibody response 2 weeks after immunization with live H. influenzae b. All three groups had a significant response (P < 0.05 using the Student's ttest for unpaired observations), and there was no significant difference in the magnitude of the response between groups. Table 5 shows that there was also no difference among the three groups in the age-related acquisition of BA activity. It also shows that after immunization with live bacteria, all three groups showed a modest increase in the percentage ofrats with detectable BA activity. The individual AC antibody responses after immunization with live bacteria were quite variable in all groups (Fig.  3) . Responses among the bacteremic and non- bacteremic rats appeared to fall into three categories: high responders (>10-fold), low responders (<2-fold), and intermediate responders (2-to 10-fold). Among the control rats, almost all were either high or low responders. Only three rats in the postimmunization sample had detectable circulating polysaccharide antigen. Interestingly, two of these rats were among the highest responders (10.0 and 6.1 jig/ml, respectively).
Passive protection experiments. Hyperimmune antiserum to H. influenzae b had high levels of protective activity against bacteremia ( Table 6 ). The 50% protection end point titer varied from 1:1,750 to 1:4,700 in separate experiments. All 11 rats who were protected against bacteremia were also protected against meningitis. Twenty-six of 29 rats with bacteremia also had meningitis. Rats inoculated with a 1:2,000 dilution of antiserum, which approached the 50% protection end point titer, had a serum AC antibody concentration bacteremia after either an i.p. or i.n. inoculation of H. influenzae b markedly declines during the first 3 weeks of life (10, 25) . This phenomenon cannot be accounted for on the basis of the appearance of serum antibodies, since these did not reach detectable levels until the rats were 5 weeks old.
Polysaccharide vaccine, which has been shown to be immunogenic in human adults and older children, appears to be either weakly or totally non-immunogenic in human infants (3, 22, 26) . The vaccine failed to elicit an immune response in adult rats. The dosages used were calculated to be proportionate by weight to immunogenic doses in humans. Nevertheless, immune responses to polysaccharide antigens are dose dependent, and a wider range of doses must be studied in rats before a final conclusion regarding immunogenicity can be reached.
Infant rats surviving severe bacteremic infection failed to develop AC or BA antibodies any more rapidly than controls. Similar observations have been made in human infants survivingH. influenzae b meningitis (17) . In contrast, Smith et al. (25) mice with pneumococcal polysaccharide (6) (5) .
A direct measurement of protective activity seemed feasible using the infant rat model. The results of passive protection experiments indicate that antibody to the capsule is the major, if not sole, protective specificity. The concentration of serum AC antibodies which protect 50% of the rats from experimental bacteremia, using the i.p. model (0.2 ug/ml), is not very different from the minimal protective concentration in humans, as predicted by calculation (0.1 Ag/ aResults are expressed as the number of bacteremic animals per total number of inoculated animals in each group. ml) or measurement (0.29 ,ug/ml) of passively protected humans with Bruton's agammaglobulinemia (23, 26) . However, a small but reproducible protective effect of antibodies to noncapsular antigens was observed with hyperimmune sera raised against unencapsulated H. influenzae. This effect was probably not due to AC antibodies, since absorption by the homologous strain abolished protective activity while not reducing the AC antibody content. Reduction of the i.p. bacterial inoculum used in the protection assay may increase the "sensitivity" of this assay to protective antibodies and thereby amplify the small protective effect observed with noncapsular antibodies. These noncapsular antigens should be further studied, since they might provide an alternative method of immunization against disease caused by H. influenzae b.
